Pharma-Bio Serv (PBSV) Income from Continuing Operations (2016 - 2025)
Historic Income from Continuing Operations for Pharma-Bio Serv (PBSV) over the last 16 years, with Q4 2025 value amounting to -$102.0.
- Pharma-Bio Serv's Income from Continuing Operations fell 10063.31% to -$102.0 in Q4 2025 from the same period last year, while for Oct 2025 it was -$110021.0, marking a year-over-year increase of 8585.16%. This contributed to the annual value of -$100463.0 for FY2025, which is 8708.07% up from last year.
- According to the latest figures from Q4 2025, Pharma-Bio Serv's Income from Continuing Operations is -$102.0, which was down 10063.31% from -$213808.0 recorded in Q3 2025.
- Pharma-Bio Serv's Income from Continuing Operations' 5-year high stood at $2.3 million during Q3 2021, with a 5-year trough of -$4.9 million in Q4 2021.
- For the 5-year period, Pharma-Bio Serv's Income from Continuing Operations averaged around -$33000.8, with its median value being $134366.0 (2022).
- Examining YoY changes over the last 5 years, Pharma-Bio Serv's Income from Continuing Operations showed a top increase of 22872.01% in 2021 and a maximum decrease of 347565.8% in 2021.
- Quarter analysis of 5 years shows Pharma-Bio Serv's Income from Continuing Operations stood at -$4.9 million in 2021, then soared by 103.56% to $173379.0 in 2022, then tumbled by 127.19% to -$47148.0 in 2023, then soared by 134.17% to $16111.0 in 2024, then tumbled by 100.63% to -$102.0 in 2025.
- Its last three reported values are -$102.0 in Q4 2025, -$213808.0 for Q3 2025, and $95353.0 during Q2 2025.